Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
Country-specific medical scientific information for Healthcare Professionals.
This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
Showing 1-10 of 251 Articles
| Title | Citation | Focus area | Phase | |
|---|---|---|---|---|
|
Topical betaxolol for treating relapsing paronychia with pyogenic granuloma-like lesions induced by epidermal growth factor receptor inhibitors |
Yen CF, et al. J Am Academy Dermatol 2018; 78(6):e143-e144 |
|
||
|
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial |
Schuler MH, et al. Ann Oncol 2016;27(3):417-23 | Non-small cell lung cancer |
|
|
|
LUME-Lung 1 Pivotal Data Trial Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial |
Reck M, et al. Lancet Oncol 2014;15(2):143-155 | Non-small cell lung cancer first line epidermal growth factor mutation-positive |
|
|
|
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas |
Norden AD, et al. J Neurooncol 2015;121(2):297-302 |
|
||
|
Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) |
Palmer D, et al. J Clin Oncol 2015;33(Suppl: Abstract 238) |
|
||
|
Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment |
Okusaka T, et al. Cancer Sci 2016;107:1791–1799 |
|
||
|
Rationale and design for the LUME-Colon 1 study: a randomised, double-blind, placebo-controlled Phase III trial of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with refractory colorectal cancer |
Van Cutsem E, et al. Clin Colorectal Cancer 2016;15(1):91-94.e1 |
|
||
|
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study |
Gottfried M, et al. J Clin Oncol 2017;12 (4): 475-485 |
|
||
|
Tumor growth over time in patients with non-small cell lung cancer (NSCLC) of adenocarcinoma histology (ACH) treated with nintedanib and docetaxel or placebo and docetaxel: analysis of data from the LUME-Lung 1 (LL1) study |
Reck M, et al. J Clin Oncol 2015;33(Suppl: Abstract e19021) | Non-squamous non-small cell lung cancer |
|
|
|
Tumor growth over time with nintedanib/docetaxel or placebo/docetaxel in adenocarcinoma NSCLC: analysis from the LUME-Lung 1 study |
Reck M, et al. J Thorac Oncol 2015;10(9 Suppl 2: Abstract MINI17.08) | Non-squamous non-small cell lung cancer |
|